Skip to main content

Table 2 Outcomes of the included patients

From: Time to peak bilirubin concentration and advanced AKI were associated with increased mortality in rheumatic heart valve replacement surgery patients with severe postoperative hyperbilirubinemia: a retrospective cohort study

Variable Value
In-hospital mortality, n (%) 45 (30.2%)
 Cause of death  
  Multiple organ failure, n (%) 25 (55.6%)
  Heart failure, n (%) 16 (35.6%)
  Hemorrhagic shock, n (%) 2 (4.4%)
  Sepsis, n (%) 2 (4.4%)
In hospital time (d) 16.20 ± 4.90
Onset time of hyperbilirubinemia (d) 2.32 ± 1.57
ICU stay time (d) 5.09 ± 5.47
Postoperative AKI, n (%) 120 (80.5%)
 Stage of AKI  
  Stage 1, n (%) 69 (46.3%)
  Stage 2, n (%) 20 (13.4%)
  Stage 3, n (%) 31 (20.8%)
CRRT, n (%) 27 (18.1%)
Use of ECMO, n (%) 9 (6.0%)
Use of IABP, n (%) 4 (2.7%)
Use of tracheotomy, n (%) 5 (3.4%)
Use of vasoactive agent, n (%) 109 (73.2%)
Duration of mechanical ventilation (d) 2.83 ± 3.14
The amount of blood transfusion (U) 31.32 ± 33.60
  1. AKI, acute kidney injury; BA, bilirubin adsorption; CRRT, continuous renal replacement therapy; ECMO, extracorporeal membrane oxygenation; IABP, intra-aortic balloon pump; ICU, intensive care unit; PE, plasma exchange